Lipella Pharmaceuticals Inc. (LIPO)
OTCMKTS · Delayed Price · Currency is USD
0.1710
-0.0241 (-12.34%)
At close: Jan 9, 2026
Lipella Pharmaceuticals Employees
As of December 31, 2024, Lipella Pharmaceuticals had 7 total employees, including 5 full-time and 2 part-time employees. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$64,964
Profits / Employee
-$888,293
Market Cap
790.16K
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7 | 0 | - |
| Dec 31, 2023 | 7 | 0 | - |
| Dec 31, 2022 | 7 | 2 | 40.00% |
| Dec 31, 2021 | 5 | 0 | - |
| Dec 31, 2020 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Glass House Brands | 374 |
| Zomedica | 152 |
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
Lipella Pharmaceuticals News
- 4 months ago - Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus - PRNewsWire
- 7 months ago - Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting - GlobeNewsWire
- 7 months ago - Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market - GlobeNewsWire
- 7 months ago - Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology - GlobeNewsWire
- 9 months ago - Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine” - GlobeNewsWire
- 11 months ago - Spartan Capital Securities, LLC Announces Key February Transactions - GlobeNewsWire
- 11 months ago - Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement - GlobeNewsWire
- 11 months ago - Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes - Benzinga